AU2017248280A1 - Treatment of depression using agents that block binding of IL-6 to IL-6 receptor - Google Patents

Treatment of depression using agents that block binding of IL-6 to IL-6 receptor Download PDF

Info

Publication number
AU2017248280A1
AU2017248280A1 AU2017248280A AU2017248280A AU2017248280A1 AU 2017248280 A1 AU2017248280 A1 AU 2017248280A1 AU 2017248280 A AU2017248280 A AU 2017248280A AU 2017248280 A AU2017248280 A AU 2017248280A AU 2017248280 A1 AU2017248280 A1 AU 2017248280A1
Authority
AU
Australia
Prior art keywords
thr
gly
ala
ser
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017248280A
Other languages
English (en)
Inventor
Guang Chen
Yu Sun
Dai Wang
Gayle WITTENBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AU2017248280A1 publication Critical patent/AU2017248280A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2017248280A 2016-04-07 2017-04-06 Treatment of depression using agents that block binding of IL-6 to IL-6 receptor Abandoned AU2017248280A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319558P 2016-04-07 2016-04-07
US62/319,558 2016-04-07
PCT/US2017/026395 WO2017177032A2 (en) 2016-04-07 2017-04-06 Treatment of depression using agents that block binding of il-6 to il-6 receptor

Publications (1)

Publication Number Publication Date
AU2017248280A1 true AU2017248280A1 (en) 2018-10-25

Family

ID=59998986

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017248280A Abandoned AU2017248280A1 (en) 2016-04-07 2017-04-06 Treatment of depression using agents that block binding of IL-6 to IL-6 receptor

Country Status (7)

Country Link
US (1) US20170291942A1 (https=)
EP (1) EP3440108A4 (https=)
JP (1) JP2019519470A (https=)
AU (1) AU2017248280A1 (https=)
CA (1) CA3019828A1 (https=)
MA (1) MA44631A (https=)
WO (1) WO2017177032A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523138A (ja) * 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
CN104119438A (zh) * 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
JP6347477B2 (ja) * 2013-12-27 2018-06-27 国立大学法人千葉大学 関節リウマチ患者に対する抗ｉｌ−６受容体抗体治療の有効性予測方法

Also Published As

Publication number Publication date
US20170291942A1 (en) 2017-10-12
WO2017177032A3 (en) 2017-11-16
MA44631A (fr) 2019-02-13
WO2017177032A2 (en) 2017-10-12
EP3440108A2 (en) 2019-02-13
EP3440108A4 (en) 2020-01-08
JP2019519470A (ja) 2019-07-11
CA3019828A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
US11197913B2 (en) Method of treating psoriatic arthritis with increased interval dosing of anti-IL12/23 antibody
EP1896073B1 (en) Anti-il-23 antibodies, compositions, methods and uses
AU2006330411B2 (en) Human anti-IL-23 antibodies, compositions, methods and uses
TWI445546B (zh) 抗-ｉｌ-６抗體，組成物，方法及用途
EP3706794A1 (en) Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
US20190345245A1 (en) Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
EP4436997A1 (en) Method of treating ulcerative colitis with anti-il23 specific antibody
US20170291942A1 (en) Treatment of Depression Using Agents that Block Binding of IL-6 to IL-6 Receptor
AU2021200025A1 (en) Human anti-IL-23 antibodies, compositions, methods and uses
AU2024204514A1 (en) Human anti-IL-23 antibodies, compositions, methods and uses
HK1118458B (en) Anti-il-23 antibodies, compositions, methods and uses
HK1170930B (en) Anti-il-23 antibodies, compositions, methods and uses
BRPI0612728A2 (pt) anticorpos de anti-il-23p19, composições, métodos e usos